RESUMEN
Antiplatelet and anticoagulation therapy after venous stenting is still not standardized, data from randomized-controlled trials are missing. Rare prothrombotic disorders and nonresponsiveness to drugs must be taken into account. This case report demonstrates successful haemostaselogical complication management in recurrent rethromboses due to underlying clopidogrel resistance and low responsiveness to anticoagulation with dabigatran after endovascular stent reconstruction of chronic pelvic and caval vein occlusion in a patient with severe postthrombotic syndrome.
Asunto(s)
Anticoagulantes/administración & dosificación , Stents Liberadores de Fármacos , Procedimientos Endovasculares/efectos adversos , Procedimientos Endovasculares/instrumentación , Vena Ilíaca , Inhibidores de Agregación Plaquetaria/administración & dosificación , Síndrome Postrombótico/terapia , Vena Cava Inferior , Anticoagulantes/efectos adversos , Angiografía por Tomografía Computarizada , Resistencia a Medicamentos , Sustitución de Medicamentos , Humanos , Vena Ilíaca/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Flebografía/métodos , Inhibidores de Agregación Plaquetaria/efectos adversos , Síndrome Postrombótico/diagnóstico por imagen , Recurrencia , Retratamiento , Resultado del Tratamiento , Vena Cava Inferior/diagnóstico por imagenRESUMEN
Thoracic endovascular aortic repair (TEVAR) is the standard of care for ruptured thoracic aortic aneurysms. A 92-year-old man had presented in stable condition but with acute severe back pain. Computed tomography revealed a ruptured thoracic aortic aneurysm. TEVAR (Valiant; Medtronic Vascular, Santa Rosa, Calif) into zone 2 with intentional coverage of the left subclavian artery was planned. After release of the stent-graft body, proximal release of the bare springs was impossible. Troubleshooting techniques were applied; but tip capture could not be released. Emergent conversion to open repair was performed. Intraoperative device deployment failure in TEVAR is rare. The findings from the present report have demonstrated the advantages of having in-house cardiac surgery backup available.